The CASZ1/uc.8+ ratio in NBE controls highly favored CASZ1 expression, whereas in cancer patients, the ratio shifted in favor of uc.8+ expression in the different stages of BlCa (Supplementary Figure S3). Here, CASZ1 is linked to cancer.